Shannon Dahl

Shannon Dahl is the Founder and Chief Executive Officer of Carve Bio, leading a consulting firm that specializes in fractional CSO roles, strategic consulting, and reimbursement strategies, particularly in immunology and cell & gene therapy. As Chief Scientific Officer at Iolyx Therapeutics and Laguna Bio, Shannon directs initiatives in autoimmunity, ophthalmology, and novel cancer immunotherapies. Additional roles include Expert-in-Residence at Digitalis Commons, contributing to ARPA-H funding programs, and advisory positions at Strand Therapeutics and HepaTx Corporation. Past experience includes advising Epic Bio and serving as Chief Scientific Officer at Cell Care Therapeutics, along with co-founding Humacyte and holding various leadership roles focused on reimbursement and technology advancement. Shannon holds degrees from the Massachusetts Institute of Technology and Duke University and completed a corporate governance program at The George Washington University.